IntroductIon 1 discovery Biology, pfizer inc., Kent, uK. the correct interpretation of data is fundamental to the study of G-protein-coupled receptor pharmacology. often, new assay technologies are assimilated into the drug discovery environment without full consideration of the data generated. in this study, the authors look at µ-opioid receptor agonists in three different assays: (1) [ 35 s]Gtpγs binding, (2) inhibition of forskolin-stimulated cAMp production, and (3) β-arrestin recruitment. Agonist-concentration effect curves were performed before and after treatment with the irreversible antagonist β-funaltrexamine, and where appropriate, these data were fitted to the operational model of agonism. the Z′ value was highest in the β-arrestin assay, followed by the [ 35 s]Gtpγs and cAMp assays. the cAMp data fitted well to the operational model, as did the [ 35 s]Gtpγs data, but the [ 35 s]Gtpγs assay led to an apparent overestimation of K A values. However, in the β-arrestin assay, data did not fit the operational model, as treatment with β-funaltrexamine reduced the emax proportionally to receptor number, with no change in ec 50 . in addition, the ec 50 values generated correlated well with affinity values. in conclusion, the β-arrestin recruitment assay does not fit with traditional pharmacological theory but is of great utility as the ec 50 value generated is a good approximation of affinity. (Journal of Biomolecular Screening 2011;16:706-716) key words: G-protein-coupled receptor, affinity, efficacy, operational model of agonism, β-arrestin recruitment, µ-opioid, potency b-Arrestin Assay Measures Affinity Journal of Biomolecular Screening 16(7); 2011 www.slas.org 707 b-Arrestin Assay Measures Affinity Journal of Biomolecular Screening 16(7); 2011 www.slas.org 709
G -protein-coupled receptors (Gpcrs) are the largest superfamily of cell surface signal transduction molecules. they are important targets in drug discovery, with an estimated 25% of prescription drugs exerting their effects through them. 1 Gpcrs exert many of their effects by activation of heterotrimeric G proteins (Gi, Gs, Gq). Following activation, G proteins divide into respective α and βγ subunits, both of which have the ability to activate or inhibit effector molecules, such as adenylate cyclase and phospholipase c. the receptor then becomes phosphorylated on intracellular serine and threonine residues by Gpcr kinases (GrKs). 2,3 the phosphorylated receptor is then bound by β-arrestin, which sterically prevents further G-protein interaction and recruits other proteins such as clathrin, which are involved in receptor internalization. in addition, β-arrestin has been shown to function as a signaling intermediate and, for instance, is involved in the activation of the MApK pathway. 4, 5 Historically, within the drug discovery environment, Gpcr agonists have been discovered through traditional second messenger assay formats, which measure the activation of G proteins (e.g., [ 35 s]Gtpγs binding) and subsequent signaling events (e.g., inhibition of forskolin-stimulated cAMp production). However, in recent years, pressure to develop more robust and high-throughput assays, with higher Z′ values and the discovery of non-G-protein-mediated signaling through Gpcrs, has led to the development of alternative assay formats, such as β-arrestin recruitment. in particular, the discoverx pathHunter assay technology used in this report uses an enzyme complementation system to detect the interaction between a tagged Gpcr and tagged β-arrestin. 6, 7 Although this assay is being used with increasing frequency, the pharmacologic values generated have not been thoroughly investigated and put into context with traditional pharmacological models.
Agonists have two properties: affinity (K A ), which is a purely drug-dependent parameter and determines how well the agonist binds to the receptor (and therefore should be equivalent for all functional endpoints), and efficacy (tau), which measures the efficiency of the transduction of binding into a response and is dependent on the ligand and the tissue/signaling pathway involved (and therefore is likely to differ for different functional endpoints). the translation of occupancy into effect is what is measured in the form of an agonist-concentration/effect ([A]/e) curve. the ability to discriminate between agonists with different efficacies is of critical importance in drug discovery. However, overexpressing recombinant systems can lead to the overestimation of the potency and efficacy of compounds, and in particular, agonists may all be termed full, that is, they produce the same maximal response. this is due to a phenomenon known as receptor reserve, in which a cell contains spare receptors (i.e., those not required to produce the maximal effect in the system). crucially, an agonist that exhibits high efficacy will need to occupy fewer receptors to lead to an effect compared with one with lower efficacy; this can lead to vast differences in the translation of in vitro to in vivo effect for compounds that appear similar in vitro. one way of distinguishing between agonists of different efficacies is pharmacologic modeling, including the operational model of agonism. 8 in this report, we have generated [A]/e curves for µ-opioid receptor agonists in a β-arrestin recruitment assay and the more traditional cAMp and [ 35 s]Gtpγs binding assays. We then used irreversible receptor activation with β-funaltrexamine and the operational model of agonism to calculate K A and efficacy values. We show that (1) a linear relationship between occupancy and effect in the β-arrestin assay means that the ec 50 values generated in this assay format correlate well with affinity values, (2) using data generated through fitting [ 35 s]Gtpγs binding data to the operational model of agonism overestimates affinity, and (3) overall, the data generated show that the data from the cAMp assay fit best with traditional pharmacologic theory. We advise that when determining agonist efficacy in a functional assay, careful consideration of the assay system and the data generated is employed before deciding on a methodology to use to calculate efficacy. in particular, although data generated in the β-arrestin assay format cannot be fitted to the operational model of agonism, it is of great utility in clearly separating the affinity and efficacy of agonists.
mEthodS

Cell culture
µ-opioid β-arrestin u2os oprM1 cells were purchased from discoverx (Birmingham, uK). cells were grown in modified eagle medium (MeM), containing 2 mM glutamax, 10% fetal bovine serum, 500 µg/ml G418, and 250 µg/ml hygromycin. cells were plated in t225 flasks at a density of 3 × 10 6 cells/flask and split as required.
β-arrestin assay
cells were plated at 7000 cells/well in white 384-well tc plates and incubated overnight. cells were then treated with 1 or 10 nM β-funaltrexamine in growth media, or growth media alone, for 30 min at 37 °c, and cells were then washed three times with growth media (5 min per wash) before treatment with compounds (duplicate wells per concentration). the agonist-loaded cell plates were then incubated at 37 °c for 90 min, before detection of the β-arrestin receptor interaction using the discoverx pathHunter detection kit according to the manufacturer's instructions.
cAMP assay
cells were plated at 15 000 cells/well in low-volume white 384-well tc plates (Greiner Bio-one ltd., stonehouse, uK) and incubated overnight. cells were then treated with 3, 10, or 30 nM β-funaltrexamine in growth media, or growth media alone, for 60 min at 37 °c. cells were then washed three times successively with growth media before addition of 250 µM iBMX (FAc) in dulbecco's Modified eagle Medium (dMeM), containing 4.5 g/l d-glucose, and subsequent addition of compounds (duplicate wells per concentration) in buffer (dpBs, 0.05% pluronic F127, 2.5% dMso) containing 10 µM forskolin (FAc). the plates were then incubated at 37 °c for 90 min, before detection of cAMp using the HtrF cAMp Hirange kit (cisbio Bioassays, Bagnols-sur-cèze cedex, France), according to the manufacturer's instructions.
Membrane preparation
cells were grown in t225 flasks up to 80% confluency in full-growth medium. cells were then treated with 1, 3, 10, or 30 nM β-funaltrexamine as appropriate in growth media, or growth media alone, for 30 min at 37 °c. the cell layer was washed three times with phosphate-buffered saline (pBs), and cells were detached from the flasks using enzyme-free cell dissociation buffer, resuspended in full-growth medium, and centrifuged for 5 min at 1000g before being washed once with pBs. cells were resuspended in ice-cold buffer (20 mM Hepes, 1 mM Mgcl 2 , 1 complete edtA-free protease inhibitor tablet 50 ml −1 ; roche diagnostics, indianapolis, in; pH 7.4). cells were homogenized at 4 °c by several strokes in a dounce glass/glass homogenizer. the homogenate was centrifuged for 20 min at 1000g, and the supernatant was collected and then centrifuged at 55 000g (4 °c) for 45 min. the resulting pellet was resuspended in buffer, and aliquots were stored at −80 °c. protein concentration was determined using the Bradford assay (sigma-Aldrich, Gillingham, uK) using bovine serum albumin (BsA) as standard.
[ 3 H]-diprenorphine competition binding
cell membranes (5 µg of protein) were incubated in duplicate with 1 nM [ 3 H]-diprenorphine in a total volume of 200 µl buffer (50 mM tris-cl pH 7.4, 3 mM Mgcl 2 , 0.2 mM edtA, 100 mM nacl, 100 µM Gtp, 0.5% BsA). nonspecific binding was determined by the inclusion of 1 µM naloxone. the reaction was initiated by the addition of membranes, and the plates were incubated at 25 °c for 2 h. the reaction was terminated by rapid filtration using a vacuum harvester with two 2-ml washes of ice-cold wash buffer (50 mM tris-cl pH 7.4, 3 mM Mgcl 2 , 0.2 mM edtA, 100 mM nacl, 0.5% BsA). the filters were soaked in 50 µl of scintillation fluid, and the amount of radioactivity present was determined by liquid scintillation counting.
[ 3 H]-diprenorphine saturation binding
cell membranes (5 µg of protein) were incubated in duplicate with between 0.01 and 10 nM [ 3 ]-diprenorphine, in a total volume of 200 µl of buffer (50 mM tris-cl pH 7.4, 3 mM Mgcl 2 , 0.2 mM edtA, 100 mM nacl, 100 µM Gtp, 0.5% BsA). nonspecific binding was determined by the inclusion of 1 µM naloxone. reactions were initiated, incubated, terminated, and read as above.
[ 35 S]GTPγS binding
cell membranes (5 µg of protein) were incubated in duplicate with 0.1 nM [ 35 s]Gtpγs in a total volume of 200 µl of buffer (50 mM tris-cl pH 7.4, 3 mM Mgcl 2 , 0.2 mM edtA, 100 mM nacl, 1 µM Gdp, 0.5% BsA) in WGA Flashplates (perkinelmer, cambridge, uK). the reaction was initiated by the addition of membranes, and the plates were incubated at 30 °c for 90 min. the reaction was terminated by centrifugation, and membrane-bound radioactivity was determined by scintillation counting.
Data analysis
data were analyzed using prisM (Graphpad software inc., san diego, cA), using in-built equations, including that of the operational model. 8 the operational model is derived from the observation that the relationship between receptor occupancy and response is hyperbolic in nature. it calculates agonist affinity (K A ) and efficacy (tau).
[A]tau (EffectMax)
is the concentration of agonist, effectMax is the maximal response of the system, K A is the equilibrium dissociation constant of the agonist-receptor complex, Rt is the receptor density, and K e is the concentration of agonist-receptor complex, which produces 50% of the maximal response.
[A]/e curves for each agonist were generated simultaneously from cells or membranes prepared from cells that had been treated either with growth media alone or with 3, 10, or 30 nM β-funaltrexamine (to deplete receptor number). each set of four [A]/e curves was then fitted simultaneously to the operational model of agonism assuming common values of effectMax, basal, and K A but allowing tau values to vary between treated and untreated curves . the fit was constrained by fitting the transducer slope to 1 (after initial fits showed this to be a good approximation) and basal values to either zero ([ 35 s]Gtpγs binding) or the basal forskolin-stimulated cAMp level determined in corresponding experiments. throughout this article, we have reported tau values from untreated cells.
Z′ is a measure of the robustness of an assay system. An assay with a Z′ of between 0.5 and 1 is regarded as an excellent assay, those with Z′s of between 0 and 0.5 are regarded as marginal assays, and an assay with a Z′ of less than 0 is considered unusable. Z′ is calculated using the following equation, 9 where "min" is the minimum signal obtained (basal) and "max" is the maximum signal obtained (using a standard agonist).
Drugs and chemicals used
[ 3 H]-diprenorphine was obtained from perkinelmer life sciences; β-funaltrexamine, d-Ala 2 , Mephe 4 , gly 5 -ol-enkephalin (dAMGo), and endomorphin 1 and 2 were obtained from sigma-Aldrich. Morphine, frakefamide, and pfizer standard 1 10 were synthesized in house.
rESuLtS the aim of this study was to compare the discoverx β-arrestin recruitment assay to more traditional Gpcr assay technologies ([ 35 s]Gtpγs binding and inhibition of forskolinstimulated cAMp production) and to determine the pharmacological significance of the data obtained in the β-arrestin recruitment assay. to counteract any variability that may be caused by differing cell backgrounds, we set up both [ 35 s]Gtpγs membrane binding and cAMp whole-cell assays in the discoverx µ-opioid β-arrestin u2os oprM1 cell line. µ-opioid receptor agonists were able to concentration dependently increase β-arrestin recruitment and [ 35 s]Gtpγs binding and inhibit forskolin-stimulated cAMp accumulation. the β-arrestin assay in this cell line exhibited a Z′ of 0.56; however, both the [ 35 s]Gtpγs assay and cAMp assay were less robust, exhibiting Z′ values of 0.21 and 0.13, respectively.
We then treated cells with β-funaltrexamine to deplete the number of receptors available for agonist activation. β-funaltrexamine is an irreversible antagonist of the µ-opioid receptor that covalently binds to lys233 of the µ-opioid receptor 11 and prevents access to the orthosteric binding site. After membrane preparation, [ 3 H]diprenorphine saturation binding experiments revealed that before treatment, the expression level was 6.19 ± 0.19 pmol mg −1 ; this decreased to 3.48 ± 0.11 pmol mg −1 (44% ± 2% reduction) after treatment with 1 nM β-funaltrexamine and 1.70 ± 0.28 pmol mg −1 (73% ± 7% reduction) after treatment with 10 nM β-funaltrexamine ( Fig. 1) . in both cases, there was no change in Kd (before treatment, 0.17 ± 0.04 nM; after treatment, 0.13 ± 0.01 nM), confirming that we had successfully removed any non-irreversibly-bound β-funaltrexamine from the membrane preparation. Agonist concentration/effect curves, for seven different agonists (dAMGo, morphine, endomorphin-1, endomorphin-2, loperamide, frakefamide, and a pfizer standard compound) were then performed in all three assay formats, before and after treatment with β-funaltrexamine.
in the β-arrestin recruitment assay, before treatment with β-funaltrexamine, all agonists were able to cause the recruitment of β-arrestin, with emax values (compared with pfizer standard 1) ranging from 16% (morphine) to 100% (pfizer standard 1; Fig. 2a; table 1) . the emax values of agonists, with the exception of dAMGo, were significantly lower than that of pfizer standard 1 (p < 0.05, one-sample t-test). treatment of cells with 10 nM β-funaltrexamine led to significant decreases in the emax values of the majority of agonists, with the exception of frakefamide and morphine (p < 0.05, unpaired t-test), and treatment of cells with 30 nM β-funaltrexamine led to significant decreases in the emax of all agonists (p < 0.05, unpaired t-test). there was no significant change in the pec 50 value of any agonist after treatment with either concentration of β-funaltrexamine (p > 0.05, unpaired t-test; Fig. 3a; table 1 ). the observed decrease in emax value was equivalent for all agonists and was independent of the emax value of the compound in untreated cells (p > 0.05 analysis of variance [AnoVA]; table 1). the percentage decrease in emax value in the β-arrestin assay was comparable to the percentage decrease in receptor number observed in the saturation binding experiments, with β-arrestin emax value decreasing 44% (compared with 44% in saturation binding; p > 0.05, unpaired t-test) after treatment with 1 nM β-funaltrexamine and 74% (compared with 73% in saturation binding; p > 0.05, t-test) after treatment with 10 nM β-funaltrexamine. the operational equation is unable to describe these data, as the model presupposes that some level of signal amplification is inherent in a functional assay, and this is not the case in the β-arrestin assay.
in the [ 35 s]Gtpγs binding assay, all agonists increased [ 35 s]Gtpγs binding in a concentration-dependent manner (Fig. 2b) , and in untreated cells, the agonists were much more potent at stimulating [ 35 s]Gtpγs binding than recruiting β-arrestin (p < 0.05 AnoVA). Also, conversely to the β-arrestin assay, all agonists tested showed a full agonist profile in the [ 35 s] Gtpγs binding assay. initial experiments in this assay showed little effect of treatment with 1 nM β-funaltrexamine. therefore, cells were treated with 3, 10, or 30 nM β-funaltrexamine to generate a family of [A]/e curves. in general, treatment with increasing concentrations of β-funaltrexamine led to decreases in emax value and rightward shifts in the ec 50 values of agonists ( Fig.  3b; table 2) . specifically, treatment with 10 or 30 nM β-funaltrexamine led to a significant decrease in the emax value of all agonists compared with the emax value obtained in untreated cells (p < 0.05, unpaired t-test); however, treatment with 3 nM β-funaltrexamine led to a significant decrease in the emax values of only endomorphin-2, frakefamide, morphine, and pfizer standard 1. unlike in the β-arrestin assay, the decrease in emax value did not correlate exactly with the decrease in receptor expression level. in terms of ec 50 values, although there was a general trend toward reduction in potency with β-funaltrexamine treatment, this reached significance only in the case of dAMGo and morphine (p < 0.05, unpaired t-test). these data were fitted to the operational model of agonism to derive K A and tau(untreated) values for the agonists (table 3), and the maximal effect possible in the system (effectMax). there was no significant difference between the tau values for different agonists (p > 0.05 AnoVA with Bonferroni post hoc analysis). Basal [ 35 s]Gtpγs binding was unchanged by treatment with β-funaltrexamine (2368 ± 321 cpm compared with 2372 ± 279 cpm; mean ± seM, n = 8). in addition, as would be predicted, the maximal possible [ 35 s]Gtpγs binding (effectMax) estimated by the operational model by fitting data for individual agonists was not significantly different (p > 0.05, AnoVA) whichever agonist was used (table 3) .
in the cAMp assay, like the [ 35 s]Gtpγs assay, in untreated cells, agonists appeared more potent than they had in the β-arrestin assay and appeared as full agonists ( Fig. 2c; table 4 ). treatment of cells with 3, 10, or 30 nM β-funaltrexamine led to decreases in emax and rightward shifts in the ec 50 of all the agonists tested ( Fig. 3c; table 4) . the effect of treatment on ec 50 value Functional properties of agonists in the β-arrestin assay were determined as described in the Methods section. potency values before and after treatment with β-funaltrexamine are expressed as pec 50 ± seM (before treatment, n = 6; after treatment, n = 3; ec 50 nM). emax values before treatment are expressed as the percentage of the maximal response of pfizer standard 1 in untreated cells (mean ± seM). For all compounds tested, the pec 50 values obtained after treatment with β-funaltrexamine were not significantly different from the pec 50 values obtained in untreated cells (p > 0.05, unpaired t-test). a. the percentage reduction in emax value after 1 nM treatment or 10 nM treatment was not significantly different between agonists (p > 0.05, analysis of variance). b. emax values obtained after treatment with β-funaltrexamine were significantly different from emax values obtained in untreated cells (p < 0.05, unpaired t-test; or one-sample t-test in the case of pfizer standard 1).
c. emax values are significantly different from those obtained with pfizer standard 1 (p < 0.05, one-sample t-test). 
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Functional properties of agonists in the inhibition of forskolin-stimulated cAMp production assay were determined as described in the Methods section. potency values before and after treatment with β-funaltrexamine are expressed as pec 50 ± seM (ec 50 nM). emax values are expressed as the percentage of the maximal response of pfizer standard 1 before treatment (mean ± seM ) . However, the data did distinguish between agonists in terms of tau(untreated) values, which were significantly higher for endomorphin-1 and frakefamide compared with pfizer standard 1 (p < 0.05 AnoVA with Bonferroni post hoc analysis). overall, fitting the cAMp data to the operational model of agonism calculated tau(untreated) values to be higher and affinity values to be lower than fitting the [ 35 s]Gtpγs binding data to the same model.
As affinity values determined in the cAMp and [ 35 s]Gtpγs assays using the operational model of agonism were not the same, we also performed competition binding assays versus [ 3 H] diprenorphine to determine the affinity of compounds. in these assays, we included 100 mM nacl and 100 µM Gtp to ensure that as far as possible we were measuring the binding affinity for the uncoupled receptor. All agonists were able to concentration dependently compete with [ 3 H]diprenorphine binding to the µ-opioid receptor (Fig. 4) ; K iGtp values were calculated from ic 50 values using the cheng-prussoff equation (table 3) . 12 We then compared the data generated in the three different functional assays and the competition binding assay. First, in terms of ec 50 values, there was poor correlation between the ec 50 values obtained in the β-arrestin assay compared with either the [ 35 s]Gtpγs binding assay or the cAMp assay (Fig. 5a) ; the slopes of the deming regression lines were 0.60 and 0.55, respectively. second, in terms of affinity values (Fig. 5b) , we observed good correlation between affinity values generated in competition binding assays and from fitting cAMp data to the operational model of agonism (deming regression slope 0.96) but a poor correlation between competition binding affinity values and those generated from fitting [ 35 s]Gtpγs binding data to the operational model of agonism (deming regression slope 0.52). third, we noted a good correlation between the ec 50 values obtained in the β-arrestin assay and both the affinity values obtained from competition binding assays (K iGtp ) and those derived from fitting data from the cAMp assay to the operational model of agonism (K A ; Fig. 5c ); the slopes of the deming regression lines were 1.06 and 0.95, respectively (the β-arrestin ec 50 values have been plotted reciprocally on this graph for clarity, showing that they fall between the two estimates of agonist affinity).
dIScuSSIon
in this study, we have compared data generated in three different functional assay systems, investigating the robustness of the assay systems and the pharmacological relevance of the data. the β-arrestin recruitment assay was clearly the best assay in terms of Z′ value, but as discussed below, the data that we have generated imply that in this assay, the potency is a direct measure of affinity, so data generated using this assay system require careful consideration.
it is important to understand the pharmacology behind the response measured to correctly interpret the data generated. Agonist efficacy can be determined from [A]/e curves using the operational model of agonism; however, this model relies on a hyperbolic relationship between occupancy and response, 8 and accordingly, β-arrestin recruitment data should not be fitted to this model as the occupancy response relationship in the β-arrestin assay is linear. simply, in the β-arrestin assay, the interaction of a single receptor (containing a 42-amino-acid fragment of β-galactosidase) with a single β-arrestin molecule (fused to an n-terminal deletion mutant of β-galactosidase) is measured. in the absence of receptors containing this fragment, no active enzyme can be formed, and only one active enzyme is formed per interacting pair. therefore, the effectMax is dependent on receptor number rather than on the system. this is inherently evident in this report, as when the µ-opioid receptor was treated with β-funaltrexamine, there was no change in agonist ec 50 and the percentage decrease in emax was directly proportional to the reduction in receptor number, as determined by saturation binding. it is also exemplified by the observation that both full and partial agonists were affected to the same extent by receptor alkylation. in this report, we have also shown that the ec 50 values in the β-arrestin assay correlate well with, and fall between, the K A values determined through fitting cAMp data to the operational model of agonism and K iGtp values determined through competition binding. this observation is limited by the low number of compounds investigated, but it is assumed that steric hindrance would prevent β-arrestin and a G-protein from being bound to any one receptor at one time (and it is assumed that a 1:1 ratio between β-arrestin and receptor is required to form an active enzyme); therefore, the observation that the ec 50 in the β-arrestin recruitment assay mimics the agonist affinity for free receptor is perhaps not surprising. However, as agonists of Gpcrs exhibit high affinity for receptor/G-protein complexes, a significant in vivo effect may occur at much lower concentration of compound than may be estimated from the β-arrestin potency data, an unusual phenomena with Gpcrs in which potency is often overestimated in recombinant cell systems.
Although the operational model cannot be used for agonist efficacy determination in the β-arrestin assay, conventional judgment denotes that for assay systems in which there is a linear relationship between occupancy and response, emax is a good indicator of efficacy. We therefore conclude that the efficacy of agonists for β-arrestin recruitment can be determined without further experimentation. this assay may also have great utility in both sAr and mutagenesis studies, where clear measurements of affinity and efficacy are key to understanding ligand/receptor interaction. the inability of receptor number to influence these in this assay should be of great advantage in determining the molecular components of β-arrestin recruitment. in addition, the assay may prove of utility in understanding the differential effect of allosteric modulators on the affinity and efficacy of the compound that they are modulating. in addition, the ability to estimate agonist affinity without the need for radioligand binding assays is an advantage. Whether the observations made in this study are illustrative of other β-arrestin assay systems requires additional experimental data. For instance, the tango β-arrestin assay 13 relies of protease-mediated cleavage of a transcription factor, and accordingly, it may be considered that signal amplification may be observed in such a system. However, in simple Bret systems, where again there is a linear relationship between occupancy and response, it is unlikely that data can be fitted to the operational model. inhibition of forskolin-stimulated cAMp production is a downstream consequence of Gαi subunit activation (as measured in [ 35 s]Gtpγs binding assays). in line with this, the majority of agonists appeared more potent in cAMp assays, and the efficacy (tau) of all agonists was significantly higher in the cAMp assay. However, it was noted that there was some difference in rank order of efficacies (tau) of agonists between the [ 35 s]Gtpγs binding and cAMp assays. Agonist-directed functional states (reviewed by Kenakin and Miller 14 ) may account for some difference in rank order. the [ 35 s]Gtpγs binding assay measures activation of at least four species of Gi/o proteins, and each of these may act differently on different isoforms of adenylate cyclase. subtle differences in agonists' abilities to activate different G-proteins, as observed for the d2 dopamine receptor, 15 may lead to a different rank order of efficacy in [ 35 s]Gtpγs binding and cAMp assays.
Agonist-directed functional states are more complicated to interpret when signaling pathways converge. β-arrestin recruitment is downstream of G-protein-stimulated GrK phosphorylation for some receptors, as has been shown by Krasel and colleagues, 16 who, using fluorescence resonance energy transfer to measure the interaction between the β2-adrenergic receptor and β-arrestin, showed that when the agonist was removed, β-arrestin dissociated rapidly from the phosphorylated receptor. However, other Gpcrs have been reported to be able to recruit β-arrestin in the absence of receptor phosphorylation. 17 in the case of the µ-opioid receptor, we and others have reported that compounds can display clearly different profiles in G-protein activation and β-arrestin recruitment, with morphine exhibiting low emax values in β-arrestin recruitment/receptor internalization but high emax values in assays measuring G-protein activation. [18] [19] [20] [21] However, emax values are not always a good indicator of efficacy. Herein, we have shown that some ligands do show agonist-directed conformational states; for instance, morphine does not differentiate from the other ligands in terms of efficacy (tau) for G-protein activation but does differentiate in terms of efficacy (emax) in the β-arrestin assay. therefore, it may be appropriate to use more than one technology to screen the target of interest depending on the desired in vivo profile.
in addition, in this report, we show that the K A values calculated from fitting the [ 35 s]Gtpγs binding data to the operational model of agonism were much higher than the K iGtp values generated from the binding assay and that the K A values calculated from fitting the cAMp data to the operational model of agonism lay between these two calculations of affinity. Agonist affinity can be overestimated using the operational model of agonism, if there is significant receptor redistribution between the different states. 22 the formation of the ternary complex (ArG) shifts the equilibrium position between A and r to the right, increasing the apparent affinity of A for r. A more downstream assay, such as cAMp, would therefore produce more accurate K A values, as there is no accumulation of ArG in this assay system. the high level of guanine nucleotides in a whole-cell downstream assay suppresses ArG formation; hence, in our competition binding assays, we used a high Gtp concentration to ensure that we were measuring binding to the free receptor, but using such high guanine nucleotide concentrations in a [ 35 s]Gtpγs binding assay would reduce the window significantly, and as a result, under the conditions used herein, there is likely to be significant accumulation of the ArG complex. Accordingly, when we attempted to increase the Gdp concentration in this assay to 10 µM (rather than 1 µM), ec 50 values for agonists were rightward shifted. Although we anticipated that this would lead to the generation of K A values more aligned with affinity values from competition binding, the reduction in our assay window (and Z′ value) meant that we could not execute this analysis. this observation was in agreement with previous studies in which increasing Gdp concentration has reduced the potency of agonists in [ 35 s]Gtpγs binding assays. 23 Furthermore, it is the view of some pharmacologists that separation of agonist affinity and receptor activation are intrinsically linked, 24 which may again lead to an overestimation of agonist affinity by a functional assay. the difference in K A values calculated from the cAMp data and those calculated in membrane binding assays may be due to the ionic differences between a whole-cell assay and a membrane preparation.
operational model fitting also allows you to ascertain the level of receptor reserve in your assay system. the greater effect on tau values rather than potency values in the [ 35 s]Gtpγs assay is indicative of little receptor reserve in the system. this is in line with previous reports in which [ 35 s]Gtpγs binding data have been fitted to the operational model, and we consider it to be due to little amplification in the system as G-protein activation is the first consequence of agonist binding. in studies comparing data generated in [ 35 s]Gtpγs binding assays and cAMp assays, as in this report, both umland et al. 25 and navratilova et al. 26 have reported little receptor reserve in the [ 35 s]Gtpγs assays, which has increased significantly in the cAMp assay, indicative of amplification in the system. previously, we have also reported that gene-reporter assays also do not generate data that can be adequately explained by operational modelling, 27 and we consider it likely that to be able to fit pharmacological data to the operational model, the assay must be a direct measure of ligandreceptor interaction, and there must be some amplification in the system.
in conclusion, we have shown that for some µ-opioid receptor agonists, efficacies for G-protein activation and β-arrestin recruitment show good correlation; however, notable exceptions, such as morphine, highlight that the design of molecules that exhibit pathway bias is a likely future direction for medicinal chemists. As expected, the [ 35 s]Gtpγs and cAMp assays gave data that fitted well to the operational model of agonism, allowing both K A and tau values to be calculated. the caveat here was the apparent overestimation of K A in the [ 35 s]Gtpγs assay system, but this analysis was able to rank compounds in terms of efficacy well. conversely, though, due to the linear occupancy-response relationship in the β-arrestin assay, the ec 50 value generated is a good approximation of agonist affinity, and the data cannot be fitted to the operational model of agonism. overall, these data exemplify that clear pharmacological understanding and analysis are key to generating decision-making data in drug discovery.
